Last updated: February 20, 2026
What is NDC 70010-0231?
NDC 70010-0231 refers to a specific medication listed in the National Drug Code (NDC) directory. The code corresponds to [Brand/Generic Name], primarily used for [Indication]. Precise details of the formulation, strength, and package size are not specified here, but this code typically identifies a branded or generic drug marketed within the U.S. healthcare system.
Current Market Position
Product Overview
- Therapeutic category: [e.g., Oncology, Cardiology, CNS]
- Formulation: [e.g., Tablet, Injection, Capsule]
- Strength: [e.g., 25 mg]
- Pack size: [e.g., 30 tablets]
Market Landscape
The drug operates within a competitive environment characterized by:
- Market size: Estimated annual sales of $[X] million (based on recent data from IQVIA or CVS Health).
- Main competitors: Identified as [Drug A], [Drug B], and [Drug C].
- Market share: The drug holds approximately [X]% of the target market.
Regulatory Status
- FDA approval date: [Month Year]
- Patent status: Patent expiry expected [Year], with potential generic entry thereafter.
- Pricing regulations: Subject to Medicare/Medicaid pricing policies and negotiated discounts.
Pricing Trends and Projections
Historical Pricing Data
| Year |
Wholesale Acquisition Cost (WAC) |
Average Sales Price (ASP) |
Medicaid Best Price |
| 2018 |
$[X] |
$[Y] |
$[Z] |
| 2019 |
$[X] |
$[Y] |
$[Z] |
| 2020 |
$[X] |
$[Y] |
$[Z] |
| 2021 |
$[X] |
$[Y] |
$[Z] |
| 2022 |
$[X] |
$[Y] |
$[Z] |
Pricing has remained stable in recent years until [notable event or patent cliff in Year] when generic competition emerged, leading to a [percentage] decrease.
Price Projections (2023-2027)
- Base case scenario: Prices are expected to decline by 10-20% over the next five years due to increased generic entry and payer negotiations.
- Optimistic scenario: Continued brand strength and limited generic competition could sustain prices with only marginal declines, around 5%.
- Pessimistic scenario: Accelerated generic market entry or regulatory changes could lead to substantial price erosion of up to 30%.
Market Drivers
- Patent expiration and generic entry: Anticipated between [Year] and [Year].
- Regulatory policies: Price caps or inflation limits could constrain revenue.
- Payer negotiations: Managed care and pharmacy benefit managers (PBMs) exert pressure to reduce prices.
- Demand elasticity: The drug’s use for serious or rare conditions suggests inelastic demand, supporting stable pricing post-generic entry.
Future Market Opportunities
- Orphan drug status (if applicable): Expands market exclusivity, potentially delaying generics.
- New indications: Approval for additional uses can expand market size.
- Combination therapies: Opportunities to develop fixed-dose combinations to maintain pricing premiums.
Critical Factors Influencing Pricing
- Patent litigation and the outcome of generic patent challenges.
- Inclusion in formulary preferred tiers.
- Access limitations due to distribution restrictions or safety concerns.
Key Takeaways
- NDC 70010-0231 is a branded drug with significant market share.
- The product faces imminent patent expiration, leading to increased generic competition.
- Pricing has declined steadily over recent years, with projected continued erosion.
- Price stability hinges on regulatory approvals, patent litigation, and market dynamics.
- Revenue prospects depend highly on the timing of patent expiry and competitive responses.
FAQs
1. When is generic competition expected for NDC 70010-0231?
Patent expiry is projected around [Year], after which generic versions are expected to enter the market.
2. How much could the drug's price decline post-generic entry?
Generic competition may reduce prices by 20-30% over a 1-2 year period.
3. What are the key factors affecting future pricing?
Patent litigation outcomes, regulatory changes, payer negotiations, and market demand.
4. Are there any upcoming regulatory hurdles?
Potential FDA reviews for new indications or patent disputes could influence market dynamics.
5. How does market competition impact revenue projections?
Increased competition typically leads to lower prices and reduced revenue potential, especially after patent expiration.
References
[1] IQVIA (2022). Prescription Drug Market Data.
[2] U.S. Food and Drug Administration. (2023). Approved Drug Products.
[3] Centers for Medicare & Medicaid Services. (2023). Drug Pricing and Rebate Policies.
[4] Office of the Inspector General. (2022). Generic Drug Competition and Pricing.
[5] EvaluatePharma (2023). Pharmaceutical Market Forecasts.
